| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.63(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,964 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
215,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$2,804,388 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
5 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fore Henrietta |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
27,000 |
|
- |
|
| Levine Arnold J |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
85,988 |
|
- |
|
| Waltrip William H |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
68,258 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2013-02-20 |
4 |
D |
$22.10 |
$110,588 |
D/D |
(5,004) |
337,746 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2013-02-20 |
4 |
D |
$22.10 |
$235,476 |
D/D |
(10,655) |
591,922 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-02-20 |
4 |
D |
$22.10 |
$75,494 |
D/D |
(3,416) |
63,771 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-02-20 |
4 |
AS |
$22.14 |
$154,980 |
D/D |
(7,000) |
212,976 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-02-20 |
4 |
D |
$22.10 |
$110,544 |
D/D |
(5,002) |
219,976 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2013-02-15 |
4 |
B |
$22.03 |
$2,567,089 |
I/I |
116,527 |
26,527,630 |
1.5 |
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
224,978 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
342,750 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
602,577 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
67,187 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
289,386 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
142,486 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-01-11 |
4 |
OE |
$3.10 |
$44,981 |
D/D |
14,510 |
220,438 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-12-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
460 |
219,978 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-11-20 |
4 |
D |
$21.08 |
$102,744 |
D/D |
(4,874) |
205,928 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2012-11-20 |
4 |
D |
$21.08 |
$102,744 |
D/D |
(4,874) |
337,750 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2012-11-20 |
4 |
D |
$21.08 |
$64,378 |
D/D |
(3,054) |
62,187 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-11-14 |
4 |
OE |
$3.10 |
$15,999 |
D/D |
5,161 |
210,802 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-11-02 |
4 |
AS |
$21.42 |
$150,162 |
D/D |
(7,000) |
205,641 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2012-11-02 |
4 |
B |
$22.35 |
$6,265,777 |
I/I |
280,348 |
26,411,103 |
1.5 |
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2012-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
284,386 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2012-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
65,241 |
|
- |
|
704 Records found
|
|
Page 15 of 29 |
|
|
0.07 (0.43%) 
